{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:14:50Z","timestamp":1793650490316,"version":"4.5.1"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T00:00:00Z","timestamp":1570924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T00:00:00Z","timestamp":1570924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["ICI1400136"],"award-info":[{"award-number":["ICI1400136"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010566","name":"Consejer\u00eda de Salud, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["PIN-0316-2017"],"award-info":[{"award-number":["PIN-0316-2017"]}],"id":[{"id":"10.13039\/501100010566","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Instituto Maimonides de Investigacion Biom\u00e9dica de C\u00f3rdoba","award":["PP13\/009"],"award-info":[{"award-number":["PP13\/009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s13555-019-00329-y","type":"journal-article","created":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T14:03:40Z","timestamp":1570975420000},"page":"655-683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Scoping Review on the Use of Drugs Targeting JAK\/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata"],"prefix":"10.1007","volume":"9","author":[{"given":"Ana M.","family":"Montilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"G\u00f3mez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro J.","family":"G\u00f3mez-Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Gay-Mimbrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Hern\u00e1ndez-Parada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Isla-Tejera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0286-4107","authenticated-orcid":false,"given":"Juan","family":"Ruano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,13]]},"reference":[{"key":"329_CR1","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/1346-8138.14322","volume":"45","author":"H Nakagawa","year":"2018","unstructured":"Nakagawa H, Nemoto O, Yamada H, Nagata T, Ninomiya N. Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis. J Dermatol. 2018;45:701\u20139.","journal-title":"J Dermatol"},{"issue":"4","key":"329_CR2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","volume":"77","author":"LY Liu","year":"2017","unstructured":"Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017;77(4):675\u201382.","journal-title":"J Am Acad Dermatol"},{"key":"329_CR3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jdcr.2018.04.006","volume":"4","author":"A Chiang","year":"2018","unstructured":"Chiang A, Ortenzio F, Juhasz MLW, Yu V, Mesinkovska NA. Balance of tofacitinib efficacy and disease flare in the treatment of alopecia universalis: a case report and review of the literature. JAAD Case Rep. 2018;4:733\u20136.","journal-title":"JAAD Case Rep"},{"issue":"Suppl","key":"329_CR4","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.jaad.2006.02.045","volume":"57","author":"AJ McMichael","year":"2007","unstructured":"McMichael AJ, Pearce DJ, Wasserman D, et al. Alopecia in the United States: outpatient utilization and common prescribing patterns. J Am Acad Dermatol. 2007;57(Suppl):S49\u201351.","journal-title":"J Am Acad Dermatol"},{"issue":"4S1","key":"329_CR5","first-page":"AB106","volume":"8","author":"S Mirzoyev","year":"2013","unstructured":"Mirzoyev S, Davis M, Torgerson R. Incidence of alopecia areata in Olmsted County, Minnesota 1990\u20132009. J Am Acad Dermatol. 2013;8(4S1):AB106.","journal-title":"J Am Acad Dermatol"},{"key":"329_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12955-016-0490-y","volume":"14","author":"K Hedayat","year":"2016","unstructured":"Hedayat K, Karbakhsh M, Ghiasi M, et al. Quality of life in patients with vitiligo: a cross-sectional study based on Vitiligo Quality of Life index (VitiQoL). Health Qual Life Outcomes. 2016;14:86.","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"329_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/bjd.14497","volume":"175","author":"F Rencz","year":"2016","unstructured":"Rencz F, Gul\u00e1csi L, P\u00e9ntek M, Wikonk\u00e1l N, Baji P, Brodszky V. Alopecia areata and health-related quality of life: a systematic review and meta-analysis. Br J Dermatol. 2016;175(3):561\u201371.","journal-title":"Br J Dermatol"},{"key":"329_CR8","doi-asserted-by":"publisher","unstructured":"Andersen L, Nyeland ME, Nyberg F. Higher self-reported severity of atopic dermatitis in adults is associated with poorer self-reported health-related quality of life in France, Germany, the UK and the US. Br J Dermatol. 2019. https:\/\/doi.org\/10.1111\/bjd.18451","DOI":"10.1111\/bjd.18451"},{"key":"329_CR9","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1242\/jcs.00963","volume":"117","author":"JS Rawlings","year":"2009","unstructured":"Rawlings JS, Rosler KM, Harrison DA. The JAK\/STAT signalling pathway. J Cells Sci. 2009;117:1281\u20133.","journal-title":"J Cells Sci"},{"key":"329_CR10","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.bcp.2011.12.024","volume":"83","author":"MM Seavey","year":"2012","unstructured":"Seavey MM, Dobrzanski P. The many faces of Janus kinase. Biochem Pharmacol. 2012;83:1136\u201345.","journal-title":"Biochem Pharmacol"},{"key":"329_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","volume":"12","author":"DM Schwartz","year":"2016","unstructured":"Schwartz DM, Bonelli M, Gadina M, O\u2019Shea JJ. Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25\u201336.","journal-title":"Nat Rev Rheumatol"},{"key":"329_CR12","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","volume":"76","author":"W Damsky","year":"2017","unstructured":"Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76:736\u201344.","journal-title":"J Am Acad Dermatol"},{"key":"329_CR13","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","volume":"186","author":"MI Jesson","year":"2011","unstructured":"Jesson MI, Kishore N, Dowty ME, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186:4234\u201343.","journal-title":"J Immunol"},{"key":"329_CR14","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1080\/09546634.2016.1277179","volume":"28","author":"A Samadi","year":"2017","unstructured":"Samadi A, Ahmad Nasrollahi S, Hashemi A, Nassiri Kashani M, Firooz A. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature. J Dermatol Treat. 2017;28:476\u201383.","journal-title":"J Dermatol Treat"},{"key":"329_CR15","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/eji.201646680","volume":"47","author":"K Welsch","year":"2017","unstructured":"Welsch K, Holstein J, Laurence A, Ghoreschi K. Targeting JAK\/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J Immunol. 2017;47:1096\u2013107.","journal-title":"Eur J Immunol"},{"key":"329_CR16","unstructured":"FDA approves Incyte\u2019s Jakafi (TM) (ruxolitinib) for patients with myelofibrosis. 2011. http:\/\/www.jakafi.com. Accessed 1 Mar 2019."},{"key":"329_CR17","first-page":"2120","volume":"69","author":"K Traynor","year":"2012","unstructured":"Traynor K. FDA approves tofacitinib for rheumatoid arthritis. Am J Health Pharm. 2012;69:2120.","journal-title":"Am J Health Pharm"},{"key":"329_CR18","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.jclinepi.2014.03.013","volume":"67","author":"HL Colquhoun","year":"2014","unstructured":"Colquhoun HL, Levac D, O\u2019Brien KK, et al. Scoping reviews: time for clarity in definition, methods and reporting scoping reviews: time for clarity in definition. J Clin Epidemiol. 2014;67:1291\u20134.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"329_CR19","doi-asserted-by":"publisher","first-page":"e028303","DOI":"10.1136\/bmjopen-2018-028303","volume":"9","author":"F G\u00f3mez-Garc\u00eda","year":"2019","unstructured":"G\u00f3mez-Garc\u00eda F, G\u00f3mez-Arias PJ, Hernandez J, et al. Drugs targeting the JAK\/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review. BMJ Open. 2019;9(5):e028303.","journal-title":"BMJ Open"},{"key":"329_CR20","volume-title":"Joanna Briggs Institute reviewers\u2019 manual 2015: methodology for JBI scoping reviews","author":"The Joanna Briggs Institute","year":"2015","unstructured":"The Joanna Briggs Institute. Joanna Briggs Institute reviewers\u2019 manual 2015: methodology for JBI scoping reviews. Adelaide: Joanna Briggs Inst.; 2015."},{"key":"329_CR21","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169:467\u201373.","journal-title":"Ann Intern Med"},{"issue":"Suppl. 105","key":"329_CR22","first-page":"76","volume":"73","author":"K Reich","year":"2018","unstructured":"Reich K, Guttman-Yassky E, Beck LA, Hu X, Pangan AL, Teixeira HD. Early response to upadacitinib in moderate-to-severe atopic dermatitis: results from a phase 2B randomized, placebo-controlled trial. Allergy Eur J Allergy Clin Immunol. 2018;73(Suppl. 105):76.","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"issue":"6","key":"329_CR23","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jdcr.2017.12.016","volume":"4","author":"GM Morris","year":"2018","unstructured":"Morris GM, Nahmias ZP, Kim BS. Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor. JAAD Case Rep. 2018;4(6):515\u20137.","journal-title":"JAAD Case Rep"},{"issue":"1","key":"329_CR24","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1111\/bjd.16686","volume":"179","author":"MS De Bruin-Weller","year":"2018","unstructured":"De Bruin-Weller MS, Forman SB, Bodhani A, et al. Effects of upadacitinib on atopic dermatitis signs, symptoms and patient-reported outcomes from a phase IIb randomized, placebo-controlled trial. Br J Dermatol. 2018;179(1):e13.","journal-title":"Br J Dermatol"},{"issue":"6","key":"329_CR25","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/1346-8138.14322","volume":"45","author":"H Nakagawa","year":"2018","unstructured":"Nakagawa H, Nemoto O, Yamada H, Nagata T, Ninomiya N. Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis. J Dermatol. 2018;45(6):701\u20139.","journal-title":"J Dermatol"},{"issue":"3","key":"329_CR26","first-page":"435","volume":"38","author":"SE Turvey","year":"2018","unstructured":"Turvey SE, Del Bel K, Ragotte R, McKinnon M. Characterization and successful treatment of a novel autosomal dominant immune dysregulatory syndrome caused by a JAK1 gain-of function mutation. J Clin Immunol. 2018;38(3):435\u20136.","journal-title":"J Clin Immunol"},{"issue":"2","key":"329_CR27","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/bjd.16014","volume":"178","author":"H Nakagawa","year":"2018","unstructured":"Nakagawa H, Nemoto O, Igarashi A, Nagata T. Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study. Br J Dermatol. 2018;178(2):424\u201332.","journal-title":"Br J Dermatol"},{"key":"329_CR28","first-page":"99","volume":"58","author":"M Vu","year":"2017","unstructured":"Vu M, Heyes C, Robertson SJ, Varigos GA, Ross G. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo. Clin Exp Dermatol. 2017;58:99\u2013100.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"329_CR29","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/bjd.14871","volume":"175","author":"R Bissonnette","year":"2016","unstructured":"Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175(5):902\u201311.","journal-title":"Br J Dermatol"},{"issue":"3","key":"329_CR30","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2015.06.045","volume":"73","author":"LL Levy","year":"2015","unstructured":"Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015;73(3):395\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"329_CR31","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.1016\/j.jid.2019.03.1074","volume":"139","author":"S Owens","year":"2019","unstructured":"Owens S, Liu H, Sun K, Venturanza M, Kuligowski M, Howell M. 998-Ruxolitinib cream significantly modulates inflammatory profiles of atopic dermatitis patients. J Investig Dermatol. 2019;139(5):S173.","journal-title":"J Investig Dermatol"},{"issue":"5","key":"329_CR32","doi-asserted-by":"publisher","first-page":"S177","DOI":"10.1016\/j.jid.2019.03.1100","volume":"139","author":"T Song","year":"2019","unstructured":"Song T, Pavel AB, Peng X, et al. 1024-Upadacitinib treatment of atopic dermatitis patients leads to reductions in epidermal hyperplasia and cellular infiltrates. J Investig Dermatol. 2019;139(5):S177.","journal-title":"J Investig Dermatol"},{"key":"329_CR33","doi-asserted-by":"publisher","first-page":"913.e9","DOI":"10.1016\/j.jaad.2018.01.018","volume":"80","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2019;80:913.e9\u2013921.e9.","journal-title":"J Am Acad Dermatol"},{"key":"329_CR34","doi-asserted-by":"publisher","unstructured":"Bissonnette R, Maari C, Forman S, et al. The oral Janus kinase\/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study. Br J Dermatol. 2019. https:\/\/doi.org\/10.1111\/bjd.17932.","DOI":"10.1111\/bjd.17932"},{"key":"329_CR35","doi-asserted-by":"publisher","first-page":"AB125","DOI":"10.1016\/j.jaci.2018.12.379","volume":"143","author":"LA Beck","year":"2019","unstructured":"Beck LA, Silverberg JI, Grebe K, et al. Eosinophil count and serum immunoglobulin e levels in atopic dermatitis: analysis of upadacitinib phase 2 study findings. J Allergy Clin Immunol. 2019;143:AB125.","journal-title":"J Allergy Clin Immunol"},{"key":"329_CR36","doi-asserted-by":"publisher","first-page":"AB128","DOI":"10.1016\/j.jaci.2018.12.387","volume":"143","author":"S Owens","year":"2019","unstructured":"Owens S, Howell MD. Ruxolitinib cream suppresses Th2 inflammation in adult patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143:AB128.","journal-title":"J Allergy Clin Immunol"},{"key":"329_CR37","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.anai.2018.09.063","volume":"121","author":"L Beck","year":"2018","unstructured":"Beck L, Hong C, Hu X, et al. Upadacitinib effect on pruritus in moderate-to-severe atopic dermatitis; from a phase 2B randomized, placebo-controlled trial. Ann Allergy Asthma Immunol. 2018;121:S21.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"329_CR38","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/jcph.1360","volume":"59","author":"VS Purohit","year":"2019","unstructured":"Purohit VS, Ports WC, Wang C, Riley S. Systemic tofacitinib concentrations in adult patients with atopic dermatitis treated with 2% tofacitinib ointment and application to pediatric study planning. J Clin Pharmacol. 2019;59:811\u201320.","journal-title":"J Clin Pharmacol"},{"key":"329_CR39","first-page":"S2","volume":"27","author":"S Piscitelli","year":"2018","unstructured":"Piscitelli S, Lee J, McHale K, et al. Cerdulatinib (DMVT-502), a novel, topical dual Janus kinase\/spleen tyrosine kinase inhibitor, improves the cellular and molecular cutaneous signature in patients with atopic dermatitis. Exp Dermatol. 2018;27:S2.","journal-title":"Exp Dermatol"},{"key":"329_CR40","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1016\/j.jid.2018.03.562","volume":"138","author":"M Gooderham","year":"2018","unstructured":"Gooderham M, Forman S, Bissonnette R, et al. The Janus kinase 1 (JAK1) inhibitor PF-04965842 reduces signs and symptoms of moderate to severe atopic dermatitis (AD). J Investig Dermatol. 2018;138:S94.","journal-title":"J Investig Dermatol"},{"key":"329_CR41","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1016\/j.jid.2018.03.525","volume":"138","author":"E Simpson","year":"2018","unstructured":"Simpson E, Wollenberg A, Bissonnette R, et al. Effects of the oral Janus kinase 1 (JAK1) inhibitor PF-04965842 on patient-reported outcomes (PROs) in adults with moderate to severe atopic dermatitis (AD). J Investig Dermatol. 2018;138:S88.","journal-title":"J Investig Dermatol"},{"issue":"6","key":"329_CR42","doi-asserted-by":"publisher","first-page":"1205.e1","DOI":"10.1016\/j.jaad.2018.02.023","volume":"78","author":"D Joshipura","year":"2018","unstructured":"Joshipura D, Alomran A, Zancanaro P, Rosmarin D. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: a 32-week open-label extension study with optional narrow-band ultraviolet B. J Am Acad Dermatol. 2018;78(6):1205.e1\u20131207.e1.","journal-title":"J Am Acad Dermatol"},{"key":"329_CR43","first-page":"93","volume":"59","author":"L Photiou","year":"2018","unstructured":"Photiou L, Sinclair R. An open label study of tofacitinib in the treatment of vitiligo. Australas J Dermatol. 2018;59:93.","journal-title":"Australas J Dermatol"},{"issue":"3","key":"329_CR44","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jamadermatol.2017.5778","volume":"154","author":"SR Kim","year":"2018","unstructured":"Kim SR, Heaton H, Liu LY, King BA. Rapid repigmentation of vitiligo using tofacitinib plus low-dose, narrowband UV-B phototherapy. JAMA Dermatol. 2018;154(3):370\u20131.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"329_CR45","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/09546634.2017.1339013","volume":"29","author":"D Joshipura","year":"2018","unstructured":"Joshipura D, Plotnikova N, Goldminz A, et al. Importance of light in the treatment of vitiligo with JAK-inhibitors. J Dermatol Treat. 2018;29(1):98\u20139.","journal-title":"J Dermatol Treat"},{"issue":"4","key":"329_CR46","doi-asserted-by":"publisher","first-page":"675.e1","DOI":"10.1016\/j.jaad.2017.05.043","volume":"77","author":"LY Liu","year":"2017","unstructured":"Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017;77(4):675.e1\u2013682.e1.","journal-title":"J Am Acad Dermatol"},{"key":"329_CR47","first-page":"e27","volume":"30","author":"S Li","year":"2017","unstructured":"Li S, Huang V. 2% topical tofacitinib cream in the treatment of vitiligo vulgaris. Pigment Cell Melanoma Res. 2017;30:e27\u2013137.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"6","key":"329_CR48","doi-asserted-by":"publisher","first-page":"1054.e1","DOI":"10.1016\/j.jaad.2017.02.049","volume":"76","author":"B Rothstein","year":"2017","unstructured":"Rothstein B, Joshipura D, Saraiya A, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol. 2017;76(6):1054.e1\u20131060.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"329_CR49","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/ced.13290","volume":"42","author":"M Vu","year":"2017","unstructured":"Vu M, Heyes C, Robertson SJ, Varigos GA, Ross G. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo. Clin Exp Dermatol. 2017;42(8):942\u20134.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"329_CR50","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","volume":"74","author":"JE Harris","year":"2016","unstructured":"Harris JE, Rashighi M, Nguyen N, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol. 2016;74(2):370\u20131.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"329_CR51","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","volume":"151","author":"BG Craiglow","year":"2015","unstructured":"Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo a pathogenesis-directed therapy. JAMA Dermatol. 2015;151(10):1110\u20132.","journal-title":"JAMA Dermatol"},{"key":"329_CR52","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jdcr.2018.04.006","volume":"4","author":"A Chiang","year":"2018","unstructured":"Chiang A, Ortenzio F, Juhasz MLW, Yu V, Mesinkovska NA. Balance of tofacitinib efficacy and disease flare in the treatment of alopecia universalis: a case report and review of the literature. JAAD Case Rep. 2018;4:733\u20136.","journal-title":"JAAD Case Rep"},{"issue":"7","key":"329_CR53","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","volume":"138","author":"A Jabbari","year":"2018","unstructured":"Jabbari A, Sansaricq F, Cerise J, et al. An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis. J Investig Dermatol. 2018;138(7):1539\u201345.","journal-title":"J Investig Dermatol"},{"issue":"6","key":"329_CR54","doi-asserted-by":"publisher","first-page":"1207.e1","DOI":"10.1016\/j.jaad.2018.02.031","volume":"78","author":"E Putterman","year":"2018","unstructured":"Putterman E, Castelo-Soccio L. Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis. J Am Acad Dermatol. 2018;78(6):1207.e1\u20131209.e1.","journal-title":"J Am Acad Dermatol"},{"key":"329_CR55","first-page":"92","volume":"59","author":"L Photiou","year":"2018","unstructured":"Photiou L, Sinclair R. An open label study of tofacitinib in the treatment of alopecia areata. Poster Presentations. Australas J Dermatol. 2018;59:92\u20133.","journal-title":"Australas J Dermatol"},{"key":"329_CR56","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1080\/09546634.2018.1466024","volume":"29","author":"JS Lee","year":"2018","unstructured":"Lee JS, Huh CH, Kwon O, Yoon HS, Cho S, Park HS. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib. J Dermatol Treat. 2018;29:819\u201322.","journal-title":"J Dermatol Treat"},{"issue":"2","key":"329_CR57","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000479722","volume":"4","author":"Y Ramot","year":"2018","unstructured":"Ramot Y, Zlotogorski A. Complete regrowth of beard hair with ruxolitinib in an alopecia universalis patient. Skin Appendage Disord. 2018;4(2):122\u20134.","journal-title":"Skin Appendage Disord"},{"issue":"3","key":"329_CR58","doi-asserted-by":"publisher","first-page":"597.e2","DOI":"10.1016\/j.jaad.2017.10.046","volume":"78","author":"LY Liu","year":"2018","unstructured":"Liu LY, Craiglow BG, King BA. Successful treatment of moderate-to-severe alopecia areata improves health-related quality of life. J Am Acad Dermatol. 2018;78(3):597.e2\u2013599.e2.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"329_CR59","doi-asserted-by":"publisher","first-page":"403.e1","DOI":"10.1016\/j.jaad.2017.10.043","volume":"78","author":"LY Liu","year":"2018","unstructured":"Liu LY, Craiglow BG, King BA. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: a pilot study of 10 patients. J Am Acad Dermatol. 2018;78(2):403.e1\u2013404.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"329_CR60","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/1203475418760512","volume":"22","author":"NU Patel","year":"2018","unstructured":"Patel NU, Oussedik E, Grammenos A, Pichardo-Geisinger R. A case report highlighting the effective treatment of alopecia universalis with tofacitinib in an adolescent and adult patient. J Cutan Med Surg. 2018;22(4):439\u201342.","journal-title":"J Cutan Med Surg"},{"issue":"12","key":"329_CR61","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1111\/ijd.14192","volume":"57","author":"L Bokhari","year":"2018","unstructured":"Bokhari L, Sinclair R. Treatment of alopecia universalis with topical Janus kinase inhibitors\u2014a double blind, placebo, and active controlled pilot study. Int J Dermatol. 2018;57(12):1464\u201370.","journal-title":"Int J Dermatol"},{"issue":"5","key":"329_CR62","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jaad.2017.06.027","volume":"77","author":"H-S Park","year":"2017","unstructured":"Park H-S, Kim M-W, Lee JS, et al. Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: a case series. J Am Acad Dermatol. 2017;77(5):978\u201380.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"329_CR63","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/ijd.13598","volume":"56","author":"A Vandiver","year":"2017","unstructured":"Vandiver A, Girardi N, Alhariri J, Garza LA. Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring. Int J Dermatol. 2017;56(8):833\u20135.","journal-title":"Int J Dermatol"},{"issue":"1","key":"329_CR64","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jaad.2017.03.024","volume":"77","author":"CB Bayart","year":"2017","unstructured":"Bayart CB, DeNiro KL, Brichta L, Craiglow BG, Sidbury R. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol. 2017;77(1):167\u201370.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"329_CR65","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1177\/1203475417716363","volume":"21","author":"M Deeb","year":"2017","unstructured":"Deeb M, Beach RA. A case of topical ruxolitinib treatment failure in alopecia areata. J Cutan Med Surg. 2017;21(6):562\u20133.","journal-title":"J Cutan Med Surg"},{"issue":"6","key":"329_CR66","doi-asserted-by":"publisher","first-page":"AB121","DOI":"10.1016\/j.jaad.2017.04.473","volume":"76","author":"N Patel","year":"2017","unstructured":"Patel N, Oussedik E, Pichardo-Geisinger RO, Feldman S. Efficacy of tofacitinib in pediatric alopecia universalis. J Am Acad Dermatol. 2017;76(6):AB121.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"329_CR67","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1001\/jamadermatol.2017.0001","volume":"153","author":"O Ibrahim","year":"2017","unstructured":"Ibrahim O, Bayart CB, Hogan S, Piliang M, Bergfeld WF. Treatment of alopecia areata with tofacitinib. JAMA Dermatol. 2017;153(6):600\u20132.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"329_CR68","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1111\/bjd.15483","volume":"176","author":"LC Strazzulla","year":"2017","unstructured":"Strazzulla LC, Avila L, Lo Sicco K, Shapiro J. Image Gallery: treatment of refractory alopecia universalis with oral tofacitinib citrate and adjunct intralesional triamcinolone injections. Br J Dermatol. 2017;176(6):e125.","journal-title":"Br J Dermatol"},{"issue":"5","key":"329_CR69","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.jid.2017.02.395","volume":"137","author":"O Ibrahim","year":"2017","unstructured":"Ibrahim O, Hogan S, Piliang M, Bergfeld W. Treatment of severe alopecia areata with the oral Janus kinase inhibitor, tofacitinib: a retrospective chart review. J Investig Dermatol. 2017;137(5):S65.","journal-title":"J Investig Dermatol"},{"issue":"5","key":"329_CR70","doi-asserted-by":"publisher","first-page":"279","DOI":"10.11622\/smedj.2017039","volume":"58","author":"BY Kim","year":"2017","unstructured":"Kim BY, Kim HS. Successful hair regrowth in a Korean patient with alopecia universalis following tofacitinib treatment. Singap Med J. 2017;58(5):279\u201380.","journal-title":"Singap Med J"},{"issue":"4","key":"329_CR71","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.jaad.2016.11.038","volume":"76","author":"L Castelo-Soccio","year":"2017","unstructured":"Castelo-Soccio L. Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis. J Am Acad Dermatol. 2017;76(4):754\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"329_CR72","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2340\/00015555-2491","volume":"97","author":"U Mrowietz","year":"2017","unstructured":"Mrowietz U, Gerdes S, Gl\u00e4ser R, Schr\u00f6der O. Successful treatment of refractory alopecia areata universalis and psoriatic arthritis, but not of plaque psoriasis with tofacitinib in a young woman. Acta Derm Venereol. 2017;97(2):283\u20134.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"329_CR73","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","volume":"76","author":"LY Liu","year":"2017","unstructured":"Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol. 2017;76(1):22\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"329_CR74","doi-asserted-by":"crossref","unstructured":"Salman A, Sarac G, Ergun T. Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature. Dermatol Online J. 2017;23(7).","DOI":"10.5070\/D3237035753"},{"issue":"2","key":"329_CR75","first-page":"47","volume":"26","author":"F Erduran","year":"2017","unstructured":"Erduran F, Ad\u0131\u015fen E, Aksakal AB. Excellent response to tofacitinib treatment in a patient with alopecia universalis. Acta Dermatovenerol Alp Pannonica Adriat. 2017;26(2):47\u20139.","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat."},{"issue":"10","key":"329_CR76","doi-asserted-by":"publisher","first-page":"750","DOI":"10.7326\/L16-0125","volume":"165","author":"M Scheinberg","year":"2016","unstructured":"Scheinberg M, Ferreira SB. Reversal of alopecia universalis by tofacitinib: a case report. Ann Intern Med. 2016;165(10):750\u20131.","journal-title":"Ann Intern Med"},{"issue":"6","key":"329_CR77","first-page":"708","volume":"33","author":"LY Liu","year":"2016","unstructured":"Liu LY, King BA, Craiglow BG. Tofacitinib for the treatment of alopecia areata in the pediatric population. . Society for Pediatric Dermatology 42nd Annual Meeting Poster Presentations July 14\u201317, 2016, Minneapolis, Minnesota. Pediatr Dermatol. 2016;33(6):708\u20139.","journal-title":"Pediatr Dermatol"},{"issue":"15","key":"329_CR78","doi-asserted-by":"publisher","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","volume":"1","author":"M Kennedy Crispin","year":"2016","unstructured":"Kennedy Crispin M, Ko JM, Craiglow BG, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1(15):e89776.","journal-title":"JCI Insight"},{"issue":"15","key":"329_CR79","doi-asserted-by":"publisher","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","volume":"1","author":"J Mackay-Wiggan","year":"2016","unstructured":"Mackay-Wiggan J, Jabbari A, Nguyen N, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016;1(15):e89790.","journal-title":"JCI Insight"},{"issue":"3","key":"329_CR80","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1159\/000450848","volume":"8","author":"SB Ferreira","year":"2016","unstructured":"Ferreira SB, Scheinberg M, Steiner D, Steiner T, Bedin GL, Ferreira RB. Remarkable improvement of nail changes in alopecia areata universalis with 10\u00a0months of treatment with tofacitinib: a case report. Case Rep Dermatol. 2016;8(3):262\u20136.","journal-title":"Case Rep Dermatol"},{"issue":"8","key":"329_CR81","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/exd.13060","volume":"25","author":"A Jabbari","year":"2016","unstructured":"Jabbari A, Nguyen N, Cerise JE, et al. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers. Exp Dermatol. 2016;25(8):642\u20133.","journal-title":"Exp Dermatol"},{"issue":"5","key":"329_CR82","doi-asserted-by":"publisher","first-page":"AB175","DOI":"10.1016\/j.jaad.2016.02.689","volume":"74","author":"W Abramovits","year":"2016","unstructured":"Abramovits W, Carviel JL, Gupta A. Tofacitinib citrate alleviates alopecia universalis symptoms in recent case study. J Am Acad Dermatol. 2016;74(5):AB175.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl. 2","key":"329_CR83","first-page":"108","volume":"10","author":"F Silvestri","year":"2016","unstructured":"Silvestri F, Rogato A, Mestroni R. Ruxolitinib for the treatment of alopecia areata. Ital J Med. 2016;10(Suppl. 2):108.","journal-title":"Ital J Med"},{"issue":"4","key":"329_CR84","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jamadermatol.2015.4445","volume":"152","author":"BG Craiglow","year":"2016","unstructured":"Craiglow BG, Tavares D, King BA. Topical ruxolitinib for the treatment of alopecia universalis. JAMA Dermatol. 2016;152(4):490\u20131.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"329_CR85","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1001\/jamadermatol.2015.3772","volume":"152","author":"A Dhayalan","year":"2016","unstructured":"Dhayalan A, King BA. Tofacitinib citrate for the treatment of nail dystrophy associated with alopecia universalis. JAMA Dermatol. 2016;152(4):492\u20133.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"329_CR86","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000445182","volume":"8","author":"F Anzengruber","year":"2016","unstructured":"Anzengruber F, Maul JT, Kamarachev J, Tr\u00fceb RM, French LE, Navarini AA. Transient efficacy of tofacitinib in alopecia areata universalis. Case Rep Dermatol. 2016;8(1):102\u20136.","journal-title":"Case Rep Dermatol"},{"issue":"8","key":"329_CR87","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/jdv.13598","volume":"30","author":"AK Gupta","year":"2016","unstructured":"Gupta AK, Carviel JL, Abramovits W. Efficacy of tofacitinib in treatment of alopecia universalis in two patients. J Eur Acad Dermatol Venereol. 2016;30(8):1373\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"329_CR88","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","volume":"2","author":"A Jabbari","year":"2015","unstructured":"Jabbari A, Dai Z, Xing L, et al. Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor baricitinib. EBioMedicine. 2015;2(4):351\u20135.","journal-title":"EBioMedicine"},{"issue":"1","key":"329_CR89","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/ajh.23871","volume":"90","author":"L Pieri","year":"2015","unstructured":"Pieri L, Guglielmelli P, Vannucchi AM. Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. Am J Hematol. 2015;90(1):82\u20133.","journal-title":"Am J Hematol"},{"issue":"9","key":"329_CR90","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","volume":"20","author":"L Xing","year":"2014","unstructured":"Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043\u20139.","journal-title":"Nat Med"},{"issue":"12","key":"329_CR91","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1038\/jid.2014.260","volume":"134","author":"BG Craiglow","year":"2014","unstructured":"Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014;134(12):2988\u201390.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"329_CR92","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4103\/ijt.ijt_21_18","volume":"10","author":"CB Shivanna","year":"2018","unstructured":"Shivanna CB, Shenoy C, Priya RA. Tofacitinib (selective Janus kinase inhibitor 1 and 3): a promising therapy for the treatment of alopecia areata: a case report of six patients. Int J Trichology. 2018;10(3):103\u20137.","journal-title":"Int J Trichology"},{"issue":"5","key":"329_CR93","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1016\/j.jid.2019.03.620","volume":"139","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Pavel AB, Page K, et al. Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2\/JAK1). J Investig Dermatol. 2019;139(5):S94.","journal-title":"J Investig Dermatol"},{"issue":"4","key":"329_CR94","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1111\/1346-8138.14644","volume":"46","author":"JS Lee","year":"2019","unstructured":"Lee JS, Yoon HS, Cho S, Park HS. Therapeutic synergy between contact dermatitis from a wig-fixing device and tofacitinib on alopecia areata. J Dermatol. 2019;46(4):e139\u201340.","journal-title":"J Dermatol"},{"issue":"4","key":"329_CR95","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jaad.2018.12.041","volume":"80","author":"YX Dai","year":"2019","unstructured":"Dai YX, Chen CC. Tofacitinib therapy for children with severe alopecia areata. J Am Acad Dermatol. 2019;80(4):1164\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"329_CR96","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jdcr.2019.02.007","volume":"5","author":"AL Rachubinski","year":"2019","unstructured":"Rachubinski AL, Estrada BE, Norris D, Dunnick CA, Boldrick JC, Espinosa JM. Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata. JAAD Case Rep. 2019;5(4):365\u20137.","journal-title":"JAAD Case Rep"},{"issue":"4","key":"329_CR97","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1111\/jdv.15383","volume":"33","author":"SC Gordon","year":"2019","unstructured":"Gordon SC, Abudu M, Zancanaro P, Ko JM, Rosmarin D. Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata. J Eur Acad Dermatol Venereol. 2019;33(4):e156\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"329_CR98","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jaad.2018.08.040","volume":"80","author":"LY Liu","year":"2019","unstructured":"Liu LY, King BA. Ruxolitinib for the treatment of severe alopecia areata. J Am Acad Dermatol. 2019;80(2):566\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"329_CR99","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000494613","volume":"235","author":"N Almutairi","year":"2019","unstructured":"Almutairi N, Nour TM, Hussain NH. Janus kinase inhibitors for the treatment of severe alopecia areata: an open-label comparative study. Dermatology. 2019;235(2):130\u20136.","journal-title":"Dermatology"},{"issue":"2","key":"329_CR100","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jaad.2018.08.041","volume":"80","author":"BG Craiglow","year":"2019","unstructured":"Craiglow BG, King BA. Tofacitinib for the treatment of alopecia areata in preadolescent children. J Am Acad Dermatol. 2019;80(2):568\u201370.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"329_CR101","doi-asserted-by":"publisher","first-page":"e12844","DOI":"10.1111\/dth.12844","volume":"32","author":"S Serdaro\u011flu","year":"2019","unstructured":"Serdaro\u011flu S, Engin B, \u00c7elik U, et al. Clinical experiences on alopecia areata treatment with tofacitinib: a study of 63 patients. Dermatol Ther. 2019;32(3):e12844.","journal-title":"Dermatol Ther"},{"key":"329_CR102","doi-asserted-by":"crossref","unstructured":"Ruiz-Villaverde R, Cuenca-Barrales C, Linares-Gonzalez L, R\u00f3denas-Herranz T. Alopecia universalis. Partial response to tofacitinib. Med Clin (Barc). 2019;153(3):e15.","DOI":"10.1016\/j.medcle.2018.11.023"},{"issue":"11","key":"329_CR103","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1001\/jamadermatol.2018.2927","volume":"154","author":"MA Borg","year":"2018","unstructured":"Borg MA, Shalabi RA, Childs R, Wells BC. Alopecia universalis and chronic graft-vs-host disease treated with ruxolitinib. JAMA Dermatol. 2018;154(11):1357\u20138.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"329_CR104","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.jdcr.2018.07.018","volume":"4","author":"BG Craiglow","year":"2018","unstructured":"Craiglow BG. Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes. JAAD Case Rep. 2018;4(10):988\u20139.","journal-title":"JAAD Case Rep"},{"issue":"8","key":"329_CR105","first-page":"914","volume":"17","author":"L Brown","year":"2018","unstructured":"Brown L, Skopit S. An excellent response to tofacitinib in a pediatric alopecia patient: a case report and review. J Drugs Dermatol. 2018;17(8):914\u20137.","journal-title":"J Drugs Dermatol"},{"issue":"7","key":"329_CR106","first-page":"800","volume":"17","author":"MW Cheng","year":"2018","unstructured":"Cheng MW, Kehl A, Worswick S, Goh C. Successful treatment of severe alopecia areata with oral or topical tofacitinib. J Drugs Dermatol. 2018;17(7):800\u20133.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"329_CR107","first-page":"41","volume":"99","author":"JW Shin","year":"2019","unstructured":"Shin JW, Huh CH, Kim MW, et al. Comparison of the treatment outcome of oral tofacitinib with other conventional therapies in refractory alopecia totalis and universalis: a retrospective study. Acta Derm Venereol. 2019;99(1):41\u20136.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"329_CR108","doi-asserted-by":"publisher","first-page":"AB285","DOI":"10.1016\/j.jaad.2018.05.1128","volume":"79","author":"Y-Y Won","year":"2018","unstructured":"Won Y-Y, Loh S-H, Lew B-L, Sim W-Y. The efficacy and safety of tofacitinib in patients with alopecia totalis. J Am Acad Dermatol. 2018;79(3):AB285.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"329_CR109","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1016\/j.jid.2018.03.462","volume":"138","author":"A Bitterman","year":"2017","unstructured":"Bitterman A, Jabbari A, Chen J, et al. Molecular correlation with clinical outcomes in an open label clinical trial of oral tofacitinib in patients with alopecia areata. J Investig Dermatol. 2017;138(5):S77.","journal-title":"J Investig Dermatol"},{"issue":"2","key":"329_CR110","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40744-017-0069-z","volume":"4","author":"M Scheinberg","year":"2017","unstructured":"Scheinberg M, de Lucena Couto Oc\u00e9a RA, Cruz BA, Ferreira SB. Brazilian experience of the treatment of alopecia universalis with the novel antirheumatic therapy tofacitinib: a case. Rheumatol Ther. 2017;4(2):503\u20138.","journal-title":"Rheumatol Ther"},{"issue":"6","key":"329_CR111","doi-asserted-by":"publisher","first-page":"AB38","DOI":"10.1016\/j.jaad.2017.04.165","volume":"76","author":"J McKesey","year":"2017","unstructured":"McKesey J, Blankenship DW, Jamison M, DeWitt C. Alopecia universalis successfully treated with tofacitinib. J Am Acad Dermatol. 2017;76(6):AB38.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"329_CR112","doi-asserted-by":"publisher","first-page":"S","DOI":"10.1016\/j.jid.2017.02.347","volume":"137","author":"A Jabbari","year":"2017","unstructured":"Jabbari A, Cerise J, Chen JC, et al. An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata. J Invest Dermatol. 2017;137(5):S.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"329_CR113","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.jid.2016.02.307","volume":"136","author":"A Jabbari","year":"2016","unstructured":"Jabbari A, Cerise J, Chen JC, et al. An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata. J Investig Dermatol. 2016;136(5):S49.","journal-title":"J Investig Dermatol"},{"issue":"6","key":"329_CR114","doi-asserted-by":"publisher","first-page":"286","DOI":"10.4103\/ijt.ijt_87_18","volume":"10","author":"AM Hosking","year":"2018","unstructured":"Hosking AM, Juh\u00e1sz M, Mesinkovska NA. Suspected herpes zoster-associated encephalitis during treatment with oral tofacitinib in alopecia universalis. Int J Trichol. 2018;10(6):286\u20138.","journal-title":"Int J Trichol"},{"issue":"4","key":"329_CR115","doi-asserted-by":"publisher","first-page":"745.e19","DOI":"10.1016\/j.jaad.2016.12.004","volume":"76","author":"R Shreberk-Hassidim","year":"2017","unstructured":"Shreberk-Hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology: a systematic review. J Am Acad Dermatol. 2017;76(4):745.e19\u2013753.e19.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"329_CR116","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.15489","volume":"33","author":"K Phan","year":"2019","unstructured":"Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019;33(5):850\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"329_CR117","first-page":"e13053","volume":"5","author":"AB de Oliveira","year":"2019","unstructured":"de Oliveira AB, Alpalh\u00e3o M, Filipe P, Maia-Silva J. The role of Janus kinase inhibitors in the treatment of alopecia areata: a systematic review. Dermatol Ther. 2019;5:e13053.","journal-title":"Dermatol Ther"},{"key":"329_CR118","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.","journal-title":"BMJ"},{"issue":"3","key":"329_CR119","doi-asserted-by":"publisher","first-page":"198","DOI":"10.12788\/j.sder.2018.041","volume":"37","author":"J Kahn","year":"2018","unstructured":"Kahn J, Deverapalli SC, Rosmarin D. JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases. Semin Cutan Med Surg. 2018;37(3):198\u2013208.","journal-title":"Semin Cutan Med Surg"},{"issue":"3","key":"329_CR120","first-page":"5","volume":"23","author":"A Cinats","year":"2018","unstructured":"Cinats A, Heck E, Robertson L. Janus kinase inhibitors: a review of their emerging applications in dermatology. Skin Ther Lett. 2018;23(3):5\u20139.","journal-title":"Skin Ther Lett"},{"issue":"3","key":"329_CR121","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jaad.2018.04.018","volume":"79","author":"AM Hosking","year":"2018","unstructured":"Hosking AM, Juhasz M, Mesinkovska NA. Topical Janus kinase inhibitors: a review of applications in dermatology. J Am Acad Dermatol. 2018;79(3):535\u201344.","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"329_CR122","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","volume":"76","author":"W Damsky","year":"2017","unstructured":"Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736\u201344.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"329_CR123","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.2174\/1874467210666170113104503","volume":"24","author":"K Kostovic","year":"2017","unstructured":"Kostovic K, Gulin SJ, Mokos ZB, Ceovic R. Tofacitinib, an oral Janus kinase inhibitor: perspectives in dermatology. Curr Med Chem. 2017;24(11):1158\u201367.","journal-title":"Curr Med Chem"},{"issue":"6","key":"329_CR124","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1080\/09546634.2016.1277179","volume":"28","author":"A Samadi","year":"2017","unstructured":"Samadi A, Ahmad Nasrollahi S, Hashemi A, Nassiri Kashani M, Firooz A. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature. J Dermatol Treat. 2017;28(6):476\u201383.","journal-title":"J Dermatol Treat"},{"issue":"4","key":"329_CR125","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40272-019-00342-w","volume":"21","author":"HL Nguyen","year":"2019","unstructured":"Nguyen HL, Anderson KR, Tollefson MM. New and emerging therapies for pediatric atopic dermatitis. Paediatr Drugs. 2019;21(4):239\u201360.","journal-title":"Paediatr Drugs"},{"issue":"2","key":"329_CR126","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40257-018-0413-2","volume":"20","author":"H He","year":"2019","unstructured":"He H, Guttman-Yassky E. JAK inhibitors for atopic dermatitis: an update. Am J Clin Dermatol. 2019;20(2):181\u201392.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"329_CR127","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.det.2018.12.007","volume":"37","author":"Y Renert-Yuval","year":"2019","unstructured":"Renert-Yuval Y, Guttman-Yassky E. What\u2019s new in atopic dermatitis. Dermatol Clin. 2019;37(2):205\u201313.","journal-title":"Dermatol Clin"},{"key":"329_CR128","first-page":"1","volume":"31","author":"MA Rodrigues","year":"2019","unstructured":"Rodrigues MA, Torres T. JAK\/STAT inhibitors for the treatment of atopic dermatitis. J Dermatol Treat. 2019;31:1\u20138.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"329_CR129","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1177\/1203475419833609","volume":"23","author":"N Relke","year":"2019","unstructured":"Relke N, Gooderham M. The use of Janus kinase inhibitors in vitiligo: a review of the literature. J Cutan Med Surg. 2019;23(3):298\u2013306.","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"329_CR130","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/1203475418824079","volume":"23","author":"EL Crowley","year":"2019","unstructured":"Crowley EL, Fine SC, Katipunan KK, Gooderham MJ. The use of Janus kinase inhibitors in alopecia areata: a review of the literature. J Cutan Med Surg. 2019;23(3):289\u201397.","journal-title":"J Cutan Med Surg"},{"key":"329_CR131","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.2147\/DDDT.S172638","volume":"12","author":"K Triyangkulsri","year":"2018","unstructured":"Triyangkulsri K, Suchonwanit P. Role of Janus kinase inhibitors in the treatment of alopecia areata. Drug Des Dev Ther. 2018;12:2323\u201335.","journal-title":"Drug Des Dev Ther"},{"issue":"9","key":"329_CR132","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.jid.2018.05.027","volume":"138","author":"EHC Wang","year":"2018","unstructured":"Wang EHC, Sallee BN, Tejeda CI, Christiano AM. JAK inhibitors for treatment of alopecia areata. J Investig Dermatol. 2018;138(9):1911\u20136.","journal-title":"J Investig Dermatol"},{"issue":"1","key":"329_CR133","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/14728214.2018.1444750","volume":"23","author":"M Iorizzo","year":"2018","unstructured":"Iorizzo M, Tosti A. Emerging drugs for alopecia areata: JAK inhibitors. Expert Opin Emerg Drugs. 2018;23(1):77\u201381.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"4","key":"329_CR134","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401\u20136.","journal-title":"J Clin Epidemiol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-019-00329-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-019-00329-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-019-00329-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T20:57:11Z","timestamp":1710363431000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-019-00329-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,13]]},"references-count":134,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["329"],"URL":"https:\/\/doi.org\/10.1007\/s13555-019-00329-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,13]]},"assertion":[{"value":"25 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}